US5298627A
(en)
*
|
1993-03-03 |
1994-03-29 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
DE4415331A1
(de)
*
|
1994-05-02 |
1995-11-09 |
Sobrevin |
Fadenspeichervorrichtung mit einstellbarem Fadenabzugswiderstand
|
US5385929A
(en)
*
|
1994-05-04 |
1995-01-31 |
Warner-Lambert Company |
[(Hydroxyphenylamino) carbonyl] pyrroles
|
HRP960312B1
(en)
|
1995-07-17 |
2001-10-31 |
Warner Lambert Co |
NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
|
US6087511A
(en)
*
|
1996-07-16 |
2000-07-11 |
Warner-Lambert Company |
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
|
US20030105154A1
(en)
*
|
2001-10-24 |
2003-06-05 |
Bisgaier Charles Larry |
Statin-carboxyalkylether combinations
|
ATE360608T1
(de)
*
|
1997-12-19 |
2007-05-15 |
Pfizer Ireland Pharmaceuticals |
Verfahren zur herstellung von 1,3-diolen
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
IN191236B
(de)
*
|
1999-05-25 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
US20040063969A1
(en)
*
|
1999-10-18 |
2004-04-01 |
Egis Gyogyszergyar Rt. |
Process for the preparation of amorphous atorvastatin calcium
|
US7411075B1
(en)
|
2000-11-16 |
2008-08-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
MXPA02004082A
(es)
*
|
1999-12-17 |
2002-10-11 |
Warner Lambert Res & Dev |
Un proceso para producir calcio de atorvastatin cristalino.
|
JP2003517038A
(ja)
|
1999-12-17 |
2003-05-20 |
ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド |
結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
|
US7608445B1
(en)
|
1999-12-29 |
2009-10-27 |
Verenium Corporation |
Nitrilases, nucleic acids encoding them and methods for making and using them
|
US7300775B2
(en)
|
1999-12-29 |
2007-11-27 |
Verenium Corporation |
Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
|
US20040014195A1
(en)
*
|
1999-12-29 |
2004-01-22 |
Diversa Corporation |
Nitrilases, nucleic acids encoding them and methods for making and using them
|
US7521216B2
(en)
*
|
1999-12-29 |
2009-04-21 |
Verenium Corporation |
Nitrilases and methods for making and using them
|
MXPA03004276A
(es)
|
2000-11-16 |
2005-04-29 |
Teva Pharma |
Hidrolisis de esteres del acido (r(r*, r*)-2 -(4-fluorofenil)- beta, delta- dihidroxi-5 -(1-metiletil)- 3-fenil-4 -((fenilamino) carbonil)- 1h-pirrol-1 -heptanoico con hidroxido de calcio.
|
US7501450B2
(en)
*
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
IL156055A0
(en)
*
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
ATE420070T1
(de)
*
|
2000-12-27 |
2009-01-15 |
Teva Pharma |
Kristalline formen von atorvastatin
|
US6476235B2
(en)
*
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
EP1724256A3
(de)
*
|
2001-01-09 |
2007-03-21 |
Warner-Lambert Company LLC |
Neues Verfahren zur Synthese von N-Phenyl-5-(4-Fluorphenyl)-1-(2-((2R,4R)-4-Hydroxy-6-Oxotetrahydropyran-2-Yl)Ethyl)-2-Isopropyl-4-Phenyl-1H-Pyrrol-3-Carbonsäureamid
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
SI20814A
(sl)
|
2001-01-23 |
2002-08-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Priprava amorfnega atorvastatina
|
SI20848A
(sl)
|
2001-03-14 |
2002-10-31 |
Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. |
Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
|
CN1524073A
(zh)
*
|
2001-06-29 |
2004-08-25 |
����-�����ع�˾ |
′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基)羰基-1H-吡咯-1-庚酸钙盐(2∶1)(阿托伐他汀)
|
IL159718A0
(en)
*
|
2001-07-06 |
2004-06-20 |
Teva Pharma |
Synthesis of intermediates for preparation of stating derivatives
|
US7199261B2
(en)
*
|
2001-07-06 |
2007-04-03 |
Teva Pharmaceutical Industries Ltd |
Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
|
US7074818B2
(en)
*
|
2001-07-30 |
2006-07-11 |
Dr. Reddy's Laboratories Limited |
Crystalline forms VI and VII of Atorvastatin calcium
|
BR0211488A
(pt)
|
2001-07-30 |
2004-08-17 |
Reddys Lab Ltd Dr |
Formas cristalinas vi e vii de atorvastina cálcica
|
KR20040026705A
(ko)
*
|
2001-08-16 |
2004-03-31 |
테바 파마슈티컬 인더스트리즈 리미티드 |
스타틴의 칼슘 염 형태의 제조 방법
|
US7563911B2
(en)
*
|
2001-08-31 |
2009-07-21 |
Morepen Laboratories Ltd. |
Process for the preparation of amorphous atorvastin calcium salt (2:1)
|
CA2412012C
(en)
*
|
2001-11-20 |
2011-08-02 |
Ed. Geistlich Soehne Ag Fuer Chemische Industrie |
Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
|
US20060020137A1
(en)
*
|
2001-11-29 |
2006-01-26 |
Limor Tessler |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
UA77990C2
(en)
*
|
2001-12-12 |
2007-02-15 |
|
Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
|
CZ296967B6
(cs)
|
2002-02-01 |
2006-08-16 |
Zentiva, A.S. |
Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
|
EP1465901A4
(de)
*
|
2002-02-19 |
2006-02-01 |
Teva Pharma |
Verfahren zur desolvatation von atorvastatin hemi-kalzium solvaten und von im wesentlichen lösungsmittelfreiem atorvastatin hemi-kalzium
|
DE10212492B4
(de)
*
|
2002-03-21 |
2012-02-02 |
Daimler Ag |
Kolbenpumpe
|
US20050113577A1
(en)
*
|
2002-04-16 |
2005-05-26 |
Karki Shyam B. |
Solid forms of slats with tyrosine kinase activity
|
AU2003251523A1
(en)
|
2002-06-13 |
2003-12-31 |
Diversa Corporation |
Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
|
US7078430B2
(en)
*
|
2002-07-08 |
2006-07-18 |
Ranbaxy Laboratories Limited |
HMG CoA-reductase inhibitors
|
US20060211761A1
(en)
*
|
2002-07-08 |
2006-09-21 |
Yatendra Kumar |
Hmg-coa-reductase inhibitors
|
ATE368661T1
(de)
*
|
2002-08-06 |
2007-08-15 |
Warner Lambert Co |
Verfahren zur herstellung von 5-(4-fluorphenyl)-1- 2-((2r,4r)-4-hydroxy-6-oxo etrahydropyran-2- yl)ethylö-2-isopropyl-4-phenyl-1h-pyrrol-3- carbonsäurephenylamid
|
US20060122403A1
(en)
*
|
2002-09-03 |
2006-06-08 |
Sanjay Suri |
Atorvastatin calcium form vi or hydrates thereof
|
SI21302A
(sl)
*
|
2002-10-11 |
2004-04-30 |
LEK farmacevtska dru�ba d.d. |
Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
|
HRP20020885B1
(en)
*
|
2002-11-11 |
2007-05-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
|
EP1424324A1
(de)
*
|
2002-11-28 |
2004-06-02 |
Teva Pharmaceutical Industries Limited |
Kristalline Form F von Atorvastatin
|
US20040198800A1
(en)
*
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
ATE407670T1
(de)
|
2002-12-20 |
2008-09-15 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
HU227041B1
(en)
*
|
2003-03-24 |
2010-05-28 |
Richter Gedeon Nyrt |
Process for the synthesis of amorphous atorvastatin calcium
|
CN1774421A
(zh)
*
|
2003-04-14 |
2006-05-17 |
沃尼尔·朗伯有限责任公司 |
制备5-(4-氟苯基)-1-[2-((2r,4r)-4-羟基-6-氧代-四氢-吡喃-2-基)乙基]-2-异丙基-4-苯基-1h-吡咯-3-羧酸苯基酰胺的方法
|
US20040248972A1
(en)
*
|
2003-05-16 |
2004-12-09 |
Ambit Biosciences Corporation |
Compounds and uses thereof
|
EP1636183A1
(de)
*
|
2003-05-16 |
2006-03-22 |
Ambit Biosciences Corporation |
Pyrrolverbindungen und deren verwendung
|
US20050182125A1
(en)
*
|
2003-05-16 |
2005-08-18 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
US7655692B2
(en)
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
US7414141B2
(en)
*
|
2003-07-25 |
2008-08-19 |
Avecia Pharmaceuticals, Ltd. |
Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin
|
JP4553899B2
(ja)
|
2003-08-21 |
2010-09-29 |
メルク フロスト カナダ リミテツド |
カテプシンシステインプロテアーゼ阻害剤
|
CN101318923A
(zh)
*
|
2003-09-17 |
2008-12-10 |
沃尼尔·朗伯有限责任公司 |
[R-(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸的结晶形式
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
AU2004293013B2
(en)
|
2003-11-19 |
2011-04-28 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
MXPA06005915A
(es)
*
|
2003-12-05 |
2006-06-27 |
Warner Lambert Co |
N-alquil pirroles como inhibidores de la hmg-coa reductasa.
|
US20050152323A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Vincent Bonnassieux |
Plug-in Wi-Fi access point device and system
|
CA2456430A1
(en)
*
|
2004-01-28 |
2005-07-28 |
Brantford Chemicals Inc. |
Improved process for the preparation of amorphous atorvastatin calcium
|
SI1727795T1
(sl)
|
2004-03-17 |
2012-05-31 |
Ranbaxy Lab Ltd |
Postopek za pripravo atorvastatin kalcija v amorfni obliki
|
AU2005232959A1
(en)
*
|
2004-04-16 |
2005-10-27 |
Pfizer Products Inc. |
Process for forming amorphous atorvastatin calcium
|
ES2739493T3
(es)
|
2004-05-05 |
2020-01-31 |
Pfizer Prod Inc |
Formas de sal de de atorvastatina con benetamina
|
MX2007000582A
(es)
*
|
2004-07-16 |
2007-03-30 |
Lek Pharmaceuticals |
Productos de degradacion oxidativa de atorvastatin calcio.
|
CA2672554C
(en)
|
2004-07-20 |
2012-01-03 |
Warner-Lambert Company Llc |
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
US7645888B2
(en)
*
|
2004-08-27 |
2010-01-12 |
Biocon Limited |
Process for the production of amorphous atorvastatin calcium
|
CA2585836A1
(en)
|
2004-10-28 |
2006-05-04 |
Warner-Lambert Company Llc |
Process for forming amorphous atorvastatin
|
US20090208539A1
(en)
*
|
2004-11-22 |
2009-08-20 |
Adel Penhasi |
Stable atorvastatin formulations
|
US20090088465A1
(en)
*
|
2004-12-02 |
2009-04-02 |
Stephen Craig Dyar |
Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
|
WO2006062876A2
(en)
|
2004-12-09 |
2006-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
CA2498978A1
(en)
|
2005-02-28 |
2006-08-28 |
Apotex Pharmachem Inc. |
An improved process for the preparation of atorvastatin and intermediates
|
CA2499047A1
(en)
*
|
2005-03-01 |
2006-09-01 |
Apotex Pharmachem Inc. |
Process for producing atorvastatin hemicalcium
|
WO2007046842A2
(en)
|
2005-03-02 |
2007-04-26 |
Merck & Co., Inc. |
Composition for inhibition of cathepsin k
|
GB2424880A
(en)
*
|
2005-04-06 |
2006-10-11 |
Generics |
Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
|
RO200700700A8
(ro)
*
|
2005-04-08 |
2015-07-30 |
Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag |
Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
TW200804345A
(en)
*
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
EP1922315B1
(de)
*
|
2005-09-09 |
2009-05-27 |
Pfizer Science and Technology Ireland Limited |
Herstellung eines atorvastatin-zwischenprodukts
|
EP1922301A1
(de)
*
|
2005-09-09 |
2008-05-21 |
Pfizer Science and Technology Ireland Limited |
Herstellung eines atorvastatin-zwischenprodukts
|
US20090216029A1
(en)
*
|
2005-09-16 |
2009-08-27 |
Yatendra Kumar |
Process for the production of atorvastatin calcium in amorphous form
|
CA2547216A1
(en)
*
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
DE602006014193D1
(de)
|
2005-11-21 |
2010-06-17 |
Warner Lambert Co |
Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
|
JP2008530146A
(ja)
*
|
2005-12-13 |
2008-08-07 |
テバ ファーマシューティカル インダストリーズ リミティド |
アトルバスタチン・ヘミカルシウムの結晶形及びその調製方法
|
EP1810667A1
(de)
|
2006-01-20 |
2007-07-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CN101395132A
(zh)
*
|
2006-03-01 |
2009-03-25 |
特瓦制药工业有限公司 |
制备阿托伐他汀半钙的晶形的方法
|
TW200813039A
(en)
|
2006-04-19 |
2008-03-16 |
Novartis Ag |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
AU2007300627B2
(en)
|
2006-09-22 |
2012-02-16 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US20100113802A1
(en)
*
|
2006-11-02 |
2010-05-06 |
Cadila Pharmaceuticals Limited |
Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
US7834195B2
(en)
*
|
2007-01-24 |
2010-11-16 |
Apotex Pharmachem Inc. |
Atorvastatin calcium propylene glycol solvates
|
EP2115153B1
(de)
|
2007-03-01 |
2013-06-05 |
BP Corporation North America Inc. |
Nitrilasen, dafür kodierende nukleinsäuren sowie verfahren zu ihrer herstellung und verwendung
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
EP3103791B1
(de)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
US20110142883A1
(en)
*
|
2007-07-20 |
2011-06-16 |
Actavis Group Ptc Ehf |
Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
|
CN101945853B
(zh)
|
2007-12-21 |
2014-08-20 |
配体药物公司 |
选择性雄激素受体调节剂(sarm)及其应用
|
EP2075246A1
(de)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
|
CN101429195B
(zh)
*
|
2008-11-03 |
2010-12-15 |
华东师范大学 |
一种高纯度阿托伐他汀重要合成中间体的制备方法
|
SI2373609T1
(sl)
|
2008-12-19 |
2013-12-31 |
Krka, D.D., Novo Mesto |
Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
|
EP2327682A1
(de)
|
2009-10-29 |
2011-06-01 |
KRKA, D.D., Novo Mesto |
Verwendung von amphiphilen Verbindungen zur gesteuerten Kristallisation von Statinen und Statin Zwischenprodukte.
|
US8115015B2
(en)
*
|
2009-01-26 |
2012-02-14 |
Cadila Healthcare Limited |
Process for the preparation of amorphous atorvastatin calcium
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
US8470805B2
(en)
*
|
2009-04-30 |
2013-06-25 |
Kaohsiung Medical University |
Processes for preparing piperazinium salts of KMUP and use thereof
|
UA109417C2
(uk)
|
2009-10-14 |
2015-08-25 |
Мерк Шарп Енд Доме Корп. |
ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
KR20120011249A
(ko)
|
2010-07-28 |
2012-02-07 |
주식회사 경보제약 |
아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
EP3327125B1
(de)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
TWI462739B
(zh)
|
2010-11-02 |
2014-12-01 |
Univ Kaohsiung Medical |
Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途
|
EP2654748B1
(de)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
EP2675440B1
(de)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin-cysteinproteasehemmer
|
CA2831730A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
BRPI1101952B1
(pt)
*
|
2011-04-25 |
2022-02-01 |
Universidade Estadual De Campinas - Unicamp |
Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida
|
WO2013004591A1
(en)
|
2011-07-01 |
2013-01-10 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Micronized crystals of atorvastatin hemicalcium
|
EP2770987B1
(de)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Neue verbindungen als erk-hemmer
|
DE102011119719A1
(de)
|
2011-11-30 |
2013-06-06 |
GEA CFS Bühl GmbH |
Verfahren zum Aufschneiden eines Lebensmittelriegels unter Verwendung eines Schwingungssensors
|
EP3919620A1
(de)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
KR102161331B1
(ko)
|
2012-11-28 |
2020-09-29 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 조성물 및 방법
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015054089A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015108988A2
(en)
|
2014-01-17 |
2015-07-23 |
Ligand Pharmaceuticals, Inc. |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
CN105085497B
(zh)
*
|
2015-06-26 |
2017-12-26 |
上海应用技术学院 |
多取代吡咯类他汀含氟衍生物及其用途
|
AU2016348638A1
(en)
|
2015-11-06 |
2018-06-07 |
Gemphire Therapeutics Inc. |
Gemcabene combinations for the treatment of cardiovascular disease
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
CN108558726A
(zh)
*
|
2018-03-14 |
2018-09-21 |
湖北广济药业股份有限公司 |
一种高纯度阿托伐他汀钙的制备方法
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
AU2020408148A1
(en)
|
2019-12-17 |
2022-06-16 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
CN111362856B
(zh)
*
|
2020-04-29 |
2023-08-18 |
福建海西新药创制股份有限公司 |
一种利用微反应装置生产阿托伐他汀钙的方法
|
CN116102482A
(zh)
*
|
2022-08-17 |
2023-05-12 |
重庆普佑生物医药有限公司 |
一种阿托伐他汀钙的制备方法
|